190 related articles for article (PubMed ID: 24721000)
1. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
[TBL] [Abstract][Full Text] [Related]
2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
4. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract][Full Text] [Related]
5. [Deep vein thrombosis revealing myeloproliferative syndrome in two adolescents].
Bertrand A; Heissat S; Caron N; Viremouneix L; Pracros JP; Javouhey E; Lachaux A; Mialou V
Arch Pediatr; 2014 May; 21(5):497-500. PubMed ID: 24709317
[TBL] [Abstract][Full Text] [Related]
6. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
7. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
Marchetti M; Falanga A
Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
[TBL] [Abstract][Full Text] [Related]
8. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
9. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
[TBL] [Abstract][Full Text] [Related]
10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
11. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
15. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
[TBL] [Abstract][Full Text] [Related]
16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
17. [Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
Araki N; Takimoto R; Chiba H; Araki H; Sato T; Iyama S; Hirakawa M; Ono K; Kawano Y; Takada K; Miyanishi K; Kobune M; Matsunaga T; Kato J; Nakamura T; Niitsu Y
Rinsho Ketsueki; 2007 Jul; 48(7):554-8. PubMed ID: 17695304
[TBL] [Abstract][Full Text] [Related]
18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
19. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
20. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
